Leopard syndrome: a report of five cases from one family in two generations.

UNLABELLED: This is the first reported family with Leopard syndrome (LS) from Bosnia and Herzegovina. We report five cases of LS from two generations of the same family. In the present series of patients from one family, all patients carry the same recurrent mutation Y279C in the PTPN11 gene, exhibiting different phenotypes and a variable expression of multiple lentigines. The diagnosis may be on clinical basis as the diagnostic clues of LS are: multiple lentigines and cafè-au-lait-spots, short stature, distinctive face, congenital heart disease, conduction abnormalities, abnormal genitalia, and sensorineural deafness. CONCLUSION: the clinical diagnosis of LS should be molecularly confirmed in the patient.

Titin A-band-specific monoclonal antibody Tit1 5H1.1. Cellular Titin as a centriolar protein in non-muscle cells.

We report the development of a new mouse anti-titin monoclonal antibody, named MAb Tit1 5H1.1, using the synthetic peptide corresponding to an amino acid sequence in the A-band of the titin molecule as immunogen. In the human skeletal muscle, MAb Tit1 5H1.1 reveals a clearly striated staining pattern, reacting with the A-band of the sarcomere. Electrophoretic, immunoblotting, and amino acid sequence analyses with ESI-MS/MS of human skeletal muscle tissue proved the target antigen of MAb Tit1 5H1.1 to be titin. The antibody reacts with titin also in non-muscle cells, producing a punctate pattern in cytoplasm and the nucleus. The most striking finding was a clear reaction of MAb Tit1 5H1.1 with centrioles in all cell types investigated so far. Immunocytochemical co-localization study with ninein-specific antibodies confirmed that the target antigen of MAb Tit1 5H1.1 is a centriole-associated protein. Experiments of the inhibition of synthesis of titin using titin siRNA duplex for the destruction of titin mRNA have shown a decreased staining of centrioles by MAb Tit1 5H1.1 in non-muscle cells and support the proposal that the target antigen of MAb is indeed titin. We suggest this anti-titin monoclonal antibody could be a valuable tool in the study of titin function and its subcellular location, both in muscle and non-muscle cells.

LEOPARD syndrome with recurrent PTPN11 mutation Y279C and different cutaneous manifestations: two case reports and a review of the literature.

LEOPARD syndrome (LS) is a heterogeneous disease characterised mainly by cutaneous manifestations. LEOPARD is the acronym for its major features-multiple lentigines, electrocardiographic conduction defects, ocular hypertelorism, pulmonary stenosis, abnormalities of (male) genitalia, retardation of growth and sensorineural deafness. As clinical manifestations are variable, molecular testing is supportive in the diagnosis of LS. We describe two unrelated LS cases with a common PTPN11 mutation Y279C and with completely different clinical features including distinct changes in skin pigmentation. In patient 1, the first complaint was hyperactive behaviour. First lentigines were presented at birth, but intensive growth began at the age of 2-4 years. Multiple dark lentigines were located mainly on the face and the upper part of the trunk, but the oral mucosa was spared. Patient 2 was born from induced labour due to polyhydramnion, and in the second week of life, mitral valve insufficiency and hypertrophic cardiomyopathy were diagnosed. Rapid growth of lentigines began at the age of 3 years. These are mostly located in the joint areas in the lower extremities; the face and upper trunk are spared from lentigines. In both cases, the rapid growth of lentigines made it possible to shift the diagnosis towards LS. Clinicians should give more consideration to rare genetic syndromes, especially in the case of symptoms from different clinical areas.

Chemokine receptor CCR5 expression in in vitro differentiating human fetal neural stem/progenitor and glioblastoma cells.

We have studied the expression of CC-chemokine receptor 5 (CCR5) at the protein level in human fetal neural stem/progenitor and glioblastoma cells in differentiation, using immunocytochemistry, routine fluorescence microscopy and confocal laser microscopy analysis. Neural stem/progenitor cells were isolated from the brain of 18-21 weeks old fetuses aborted due to medical indications, and propagated in vitro as neurospheres. Glioblastoma cells were isolated from tumour biopsies and propagated in vitro as spheres according to the same methods as fetal neural cells. Two stem/progenitor cell neurosphere and two glioblastoma spheroid cultures were initiated to differentiate using RA and cAMP. The cells were fixed and analyzed immunocytochemically on the 1st, 3rd, and 8th days of the differentiation. The expression of CCR5 was localized mainly in the cell nuclei, and was usually much weaker, if at all, in cytoplasm. Confocal laser microscopy analysis confirmed the same location. The expression of CCR5 was the highest one on the 3rd day of differentiation in all cultures, but showed also distinct differences between cultures, and in normal fetal differentiated stem/progenitor cells the expression of CCR5 was much weaker than in differentiated glioblastoma spheric cells.

CC-chemokine receptor CCR5-del32 mutation as a modifying pathogenetic factor in type I diabetes.

The purpose of this study was to determine the CCR5-del32 allele frequency in type I (insulin-dependent) and type II (noninsulin-dependent) diabetes patients, and to test whether and how this mutation is associated with both types of diabetes. Thirty-eight type I diabetes and 111 type II diabetes patients' genotyping was performed by polymerase chain reaction assaying, and amplified products were digested with restriction enzyme EcoRI. The results were analyzed using statistical methods. No statistical differences were found in CCR5-del32 allele frequencies in types I and II diabetes patients compared with the control group of native Estonians. However, an association exists between CCR5 gene polymorphism and the clinical course of type I diabetes. In the case of wild-type CCR5, the disease starts at an earlier age. In type II diabetes, there was a difference between genotypes in morbidity to concomitant diseases, being higher in the CCR5 wild-type genotype.